Research
Hormonal
The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.
Healthcare providers may need to adapt to new treatment protocols involving poly-agonists.
StrongSupportsmedium confidence
The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.
Why this rating
The claim is based on emerging evidence regarding new treatment options.
Source
<scp>Glucagon‐like peptide</scp>‐1, glucose‐dependent insulinotropic polypeptide, and glucagon receptor poly‐agonists: a new era in obesity pharmacotherapy
Is‐haq O. Malik et al. · Obesity · 2022
DOI 10.1002/oby.23521
otherCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →